NMRA Stock Forecast & Price Target

Neumora Therapeutics is viewed favorably because navacaprant, its lead asset, has a strong chance of succeeding in its Phase 3 MDD program and could deliver a differentiated treatment with US sales potential of $750M in 2028 and $3B at peak. The bull case is further supported by reduced mechanism-of-action risk in the Phase 2 BPD study, which has data expected in 2H25, and by meaningful pipeline catalysts including NMRA-511 MAD data in 4Q26, NMRA-898 Phase 1 data in 2H26, and NMRA-215’s planned clinic entry in 2026. Beyond the lead program, the company’s broad neuroscience portfolio of seven clinical and preclinical assets positions it for multiple shots at first- or best-in-class outcomes across underserved neuropsychiatric and neurodegenerative diseases.

Neumora Therapeutics is viewed negatively because navacaprant’s KOASTAL-2 and KOASTAL-3 readouts failed to separate from placebo on both the primary MADRS endpoint and the SHAPS measure, undermining the core KORA thesis and leaving no meaningful efficacy signal despite prior biological rationale. The company is also cutting 35% of its workforce and expects only $10M in annualized savings, a sign of cost pressure rather than operating leverage, while sales and costs tied to navacaprant are being removed from the model. With no FDA-approved products, no current revenue, and a pipeline still exposed to clinical, regulatory, and dilution risk, the investment case depends on uncertain future execution.